Influence of Vitamin E Supplementation on Glycaemic Control: A Meta-Analysis of Randomised Controlled Trials

Renfan Xu1, Shasha Zhang2, Anyu Tao3, Guangzhi Chen2*, Muxun Zhang1*

1 Department of Endocrinology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, People’s Republic of China, 2 Department of Internal Medicine and Gene Therapy Center, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, People’s Republic of China, 3 Department of Medical Ultrasound, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, People’s Republic of China

Abstract

Observational studies have revealed that higher serum vitamin E concentrations and increased vitamin E intake and vitamin E supplementation are associated with beneficial effects on glycaemic control in type 2 diabetes mellitus (T2DM). However, whether vitamin E supplementation exerts a definitive effect on glycaemic control remains unclear. This article involves a meta-analysis of randomised controlled trials of vitamin E to better characterise its impact on HbA1c, fasting glucose and fasting insulin. PubMed, EMBASE and the Cochrane Library were electronically searched from the earliest possible date through April 2013 for all relevant studies. Weighted mean difference (WMD) was calculated for net changes using fixed-effects or random-effects models. Standard methods for assessing statistical heterogeneity and publication bias were used. Fourteen randomised controlled trials involving individual data on 714 subjects were collected in this meta-analysis. Increased vitamin E supplementation did not result in significant benefits in glycaemic control as measured by reductions in HbA1c, fasting glucose and fasting insulin. Subgroup analyses revealed a significant reduction in HbA1c (−0.58%, 95% CI −0.83 to −0.34) and fasting insulin (−9.0 pmol/l, 95% CI −15.90 to −2.10) compared with controls in patients with low baseline vitamin E status. Subgroup analyses also demonstrated that the outcomes may have been influenced by the vitamin E dosage, study duration, ethnic group, serum HbA1c concentration, and fasting glucose control status. In conclusion, there is currently insufficient evidence to support a potential beneficial effect of vitamin E supplementation on improvements of HbA1c and fasting glucose and insulin concentrations in subjects with T2DM.

Introduction

Type 2 diabetes mellitus (T2DM) is a global health problem affecting almost 336 million people worldwide or approximately 8.3% of the world population, and the number of affected individuals will dramatically increase in the next 20 years [1]. Poor glycaemic control is responsible for the long-term negative outcomes in T2DM subjects, including microvascular and macrovascular complications, such as cardiovascular events, renal failure, blindness and peripheral neuropathy [2]. Appropriate management of hyperglycaemia is needed to reduce morbidity and the number of complications associated with T2DM.

The association between oxidative stress and T2DM has long been recognised and is based on the observation that hyperglycaemia, hyperinsulinaemia, and insulin resistance can enhance free radical generation and thus contribute to oxidative stress [3]. Oxidative stress can in turn promote haemoglobin glycation [4,5] and impair insulin signalling and β-cell insulin secretion in T2DM [6,7]. Thus, it is reasonable to postulate that antioxidants, such as vitamin E, may have benefits effects on glycaemic control in T2DM.

Vitamin E is a powerful lipid-soluble antioxidant that reduces oxidative stress and decreases the oxidative stress-associated damage in T2DM [8]. Anti-hyperglycaemic effects of vitamin E have been hypothesised, tested in laboratory and human studies, and have gained biological plausibility. Observational studies have indicated that vitamin E intake was inversely related to a risk of T2DM [9]. Furthermore, in patients with established T2DM, regular vitamin E supplementation is associated with a significant improvement in glycaemic control [10], which provide justification for trials evaluating vitamin E supplementation and glycaemic control in T2DM subjects.

There are several possible mechanisms underlying the association between vitamin E and glucose metabolism. Vitamin E may prevent the glycosylation of haemoglobin by inhibiting the formation of advanced glycosylation endproducts (AGEs) [11]. Vitamin E can also mitigate the long-term pancreatic β-cell dysfunction caused by oxidative stress in T2DM [12]. Vitamin E supplementation was also found to be associated with other disorders, including Nonalcoholic Steatohepatitis [13] and age-related cataract [14], while there is no evidence to support the use of vitamin E supplements for prevention of cardiovascular diseases [15] and stroke [16].

Vitamin E (tocopherols and tocotrienols) is an essential micronutrient that is acquired primarily through the consumption of fruit, vegetable oils, nuts, and green leafy vegetables [17].
addition, vitamin E capsules are readily available and often supplied for healthy people, and approximately 12.7% of the adult population in the United States takes vitamin E as dietary supplements [18]. Given that vitamin E intake is simple, safe, and inexpensive, the vitamin E supplementation may represent a common and easily obtainable treatment for glycaemic control.

The objective of this meta-analysis was to combine evidence from randomised controlled trials (RCTs) to assess the effect of vitamin E supplementation on change in HbA1c, a well-established clinical marker of long-term glycaemic control, and on fasting glucose and fasting insulin levels in subjects with T2DM.

Experimental Methods

Search selection

We searched the PubMed (http://www.ncbi.nlm.nih.gov/pubmed/), EMBASE (http://www.embase.com/) and Cochrane library databases (http://www.cochrane.org/) from their inception until April 2013 for trials that examined the effects of vitamin E on HbA1c, glucose control and insulin sensitivity in humans. The following search terms were used: (vitamin E OR alpha-tocopherol OR tocopherols OR tocotrienols) AND (glucose OR hyperglycaemia OR glyc(a)emia OR insulin OR insulin sensitivity OR insulin resistance OR HbA1c OR glycated protein or glycated albumin OR fructosamine OR diabetes). The search was confined to human studies. Manual recursive searches were also conducted on references from review articles and published randomised controlled trials that met the inclusion criteria. There was no restriction by language or publication status.

Study selection

Potentially relevant studies were selected based on the following inclusion criteria: (1) randomised controlled trials with either a parallel or a crossover design; (2) adults with T2DM supplied with a vitamin E supplementation that is currently FDA-approved for at least 6 weeks treatment; (3) fasting glucose, fasting insulin, HbA1c or glycated haemoglobin levels were described in the clinical trials; And (4) studies used a concurrent control group, and the difference between the treatment and the control groups was limited to vitamin E. Exclusion criteria were as follows: (1) trials that enrolled children, pregnant women, or patients with type 1 diabetes; (2) patients were supplied with both vitamin E and other antioxidants; and (3) trials with abstracts only.

Data extraction

Two investigators independently selected the trials and extracted the data, and disagreements or uncertainties were resolved by consensus. Extracted data included study characteristics (author, publication status, year, design), treatment characteristics (type of intervention, dosage, frequency, duration), and participant characteristics (sample, mean age, gender, race/ethnicity, serum vitamin E level, mean HbA1c and fasting glucose levels). Primary outcome measures included the net changes in plasma concentrations of glycated haemoglobin (HbA1c), fasting glucose levels, and fasting insulin concentrations after vitamin E supplementation. The secondary outcome included changes in the homoeostatic model assessment of insulin resistance (HOMA-IR), postprandial glucose and insulin concentrations, total cholesterol (TC), triglycerides (TG), high density lipoprotein cholesterol (HDL-c), low density lipoprotein cholesterol (LDL-c), systolic blood pressure (SBP) and diastolic blood pressure (DBP).

Quality assessment

The quality of the included studies was assessed using the Jadad scoring system [19]. Trials scored one point for each area addressed in the study (randomisation, double-blinding, description of withdrawals and dropouts, generation of random numbers and allocation concealment), with a possible score between 0 and 5. Trials were subclassified as high-quality (Jadad score ≥4) or low-quality (Jadad score of 2 or 3).

Statistical analyses

The statistical analysis was performed with RevMan software version 5 (Cochrane Collaboration). The mean change in the outcome variables from baseline was treated as a continuous variable, and the weighted mean difference was calculated as the difference between the mean in the vitamin E group and control groups. The significance of any mean changes was evaluated using the WMD and 95% CIs with fixed-effect or random-effect models. If the variances for the mean changes were not reported directly, the variances were imputed from the exact P value, CIs, or individual variances from the vitamin E group and the control group [20]. Missing variances for paired differences were imputed by assuming a correlation coefficient of 0.5 between variances at baselines and ends of trials according to the method of Follmann et al [21]. We assumed equal variances during the trial and between intervention and control groups.

Heterogeneity was assessed using the Cochrane Q statistic and the inconsistency index (I²), where a P value<0.10 was considered significant, and measured in-consistency (I²) statistics, with a measurement >50% taken to indicate substantial heterogeneity [22]. A random-effect model was used to analyse the results with significant heterogeneity. Otherwise, a fixed-effect model was used for outcomes without obvious heterogeneity [23]. Publication bias was assessed using funnel plots and Egger’s test [24]. To explore the possible influence of covariates on net changes, subgroup analyses were conducted to evaluate the effects of the following factors on primary outcomes (HbA1c, fasting glucose and insulin concentrations); vitamin E dosages, ethnic groups, vitamin E duration, baseline HbA1c concentrations, baseline fasting glucose concentrations and the baseline serum vitamin E concentrations of the participants. A P value <0.05 was considered to be statistically significant in this trial, unless otherwise specified.

Results

Literature search

We identified 5073 potentially relevant articles from the PubMed, EMBASE and Cochrane library databases, 5021 of which were determined to be irrelevant after review of the titles and abstracts. 32 trials proceeded to a detailed evaluation of the complete report, and a further 38 were excluded. A total of 14 trials met the selection criteria for the current meta-analysis. A flow describing article selection for this meta-analysis is shown in Figure 1.

Study description

Fourteen published studies with a total of 714 participants, including 363 subjects in the vitamin E group and 551 patients in the control group, were identified in this meta-analysis [25–38]. The characteristics of the studies and participants are outlined in Table 1. Three primary outcomes measures were examined: HbA1c (12 studies) [25–36], fasting glucose (12 studies) [25–31,34,36–38] and fasting insulin (6 studies) [29–31,36–38]. Among them, one trial examined the effect of vitamin E in both type 1 and type 2 diabetes; only groups with type 2 diabetes were selected for
The results for fasting glucose were reported in 12 studies representing 587 participants, including 290 controls. Meta-analyses suggested that vitamin E supplementation, compared with a placebo or control, resulted in no statistically significant improvement (0.12 mmol/l, 95% CI: −0.34 to 0.36 mmol/l, P = 0.60, Figure 3) in fasting glucose status. The degree of heterogeneity was significant (I² = 67%; P < 0.0001), and random-effects models were performed in this meta-analysis.

The mean change in fasting insulin concentrations was reported in 6 studies, representing 394 participants, and was not significantly decreased in the intervention groups (−4.54 pmol/l, 95% CI: −13.16 to 4.08 pmol/l, P = 0.30, Figure 4) compared to control arms. Significant heterogeneity (I² = 89%; P < 0.0001) was observed, and the results are reported on the basis of random-effects models.

Subgroup analysis

Subgroup analyses were conducted to explore the dose-effect relationship, study-duration effects, ethnic group variation, and differences in baseline HbA1c, fasting glucose and serum vitamin E concentrations. The results are summarised in Table 2.

In general, the reduction in HbA1c and fasting insulin were greater in studies with low serum vitamin E concentrations, with mean changes of −0.38 (95% CI: −0.83, −0.34) and −9.0 pmol/l (95% CI: −15.90, −2.10 pmol/l) respectively. In contrast, fasting glucose decreased significantly in studies with normal vitamin E concentrations (−0.57 mmol/l; 95% CI: −0.87, −0.28 mmol/l), Trials with low serum vitamin E concentrations were limited in this meta-analysis, so more trials are needed in the following research area.

Subgroup analysis also suggested that HbA1c and fasting insulin were reduced to a greater degree in studies with higher HbA1c concentrations (≥8%), with mean changes of −0.49 (95% CI: −0.71, −0.28) and −10.67 pmol/l (95% CI: −12.31, −9.02 pmol/l). In contrast, there was a negative dose-response relationship between HbA1c concentrations (<8%) and the reduction in fasting glucose. Significant reductions in HbA1c were also observed in studies with poor fasting glucose concentrations (≥8 mmol/l) (−0.44 mmol/l; 95% CI: −0.62, −0.26 mmol/l).

A significant reduction in HbA1c was observed in studies with higher vitamin E doses (>400 mg/d), with a net change of −0.35 (95% CI: −0.63, −0.07). Similarly, concentrations of fasting insulin declined significantly in studies with longer vitamin E treatment durations (>12 wk) (−9.0 pmol/l; 95% CI: −15.90, −2.10 pmol/l). Western population with vitamin supplementation also yielded significant effect on HbA1c (−0.34; 95% CI: −0.58, −0.09) compared with controls. In conclusion, although there are significant results in subgroup analysis, more trials with larger subjects are needed to make a definite conclusion.

A sensitivity analysis was performed by excluding three trials (Economides 2005, Balasingh 2005, Ward 2007) which used an oil for placebo. The exclusion of trials resulted in greater reductions in HbA1c (−0.30, 95% CI: −0.59, −0.02; P = 0.04), which significantly influenced the results. While, after exclusion these trials, the pooled reductions in fasting glucose and fasting insulin were not significantly influenced, with 0.19 mmol/l (95% CI: −0.33, 0.71 mmol/l; P = 0.47) and −4.33 pmol/l (95% CI: −13.06, 4.41 pmol/l; P = 0.33), respectively. In a sensitivity analysis, after exclusion the trial (Park 2002) with digestive pill, the pooled reductions in HbA1c, fasting glucose and fasting insulin were not significantly influenced, with −0.24 (95% CI: −0.50, 0.03; P = 0.08), 0.12 mmol/l (95% CI: −0.35, 0.59 mmol/l;
Table 1. Characteristic of experimental trials included in the meta-analysis.

| Trial          | Country | Vitamin E group intervention | Control group | Duration weeks | Study Size(n) | Mean age (year) | Male(%) | Diabetes duration(years) | Trial design | Baseline HbA1c(%) | Baseline FPG(mmol/l) | Baseline Vit E (mmol/l) |
|----------------|---------|-------------------------------|---------------|----------------|----------------|-----------------|---------|--------------------------|--------------|------------------|-----------------------|------------------------|
| Paolisso 1993  | Italy   | d-α-tocopherol 900 mg/d       | Placebo       | 12             | 25             | 71.3            | 71.3              | 8.4     | 8.4                      | C1           | 7.0              | 8.2                   | 16.3                   |
| Reven 1995     | USA     | dl-α-tocopherol 1600 IU/d     | Placebo       | 10             | 10             | 60.8            | 61.8              | 100     | 100                      | P            | 7.7              | 9.9                   | 35                     |
| Tutuncu 1998   | Turkey  | dl-α-tocopherol acetate 900 mg/d | Placebo       | 24             | 11             | 51.2            | 59.3              | 18.2    | 10                       | P            | 7.5              | 7.2                   | —                      |
| Gads 1999      | UK      | α-tocopherol 1600 IU/Placebo  |               | 8              | 23             | 56.4            | 57.9              | 65.2    | 84                       | P            | 6.9              | 9.6                   | 27.8                   |
| Paolisso 2000  | Italy   | Vitamin E 600 mg              | Placebo       | 8              | 20             | 58.3            | 56.7              | 45      | 60                       | P            | 7.7              | 8.3                   | 16.9                   |
| Manzella 2001  | Italy   | All-rac-α-tocopherolAcetate 600 mg/d | Sodium citrate | 16             | 25             | 64.3            | 65.1              | —       | —                        | P            | 8.2              | 9.1                   | 7.1                    |
| Park 2002      | Korea   | α-tocopherol 200 mg/Digestive pill |             | 8              | 48             | 49.4            | 49.5              | 56.3    | 62.8                      | P            | 10.9             | 10.4                  | 25.5                   |
| Chen 2004      | China   | Vitamin E 200 mg              | Placebo       | 52             | 41             | 52              | 52.4              | 51.2    | 48.8                      | <1           | <1               | P                     | 7.6                    |
| Economides 2005| USA     | All-rac-α-tocopherol Acetate 1800 IU/d | Soybean oil | 24             | 25             | 59              | 59                | 56.7    | 56.7                      | 9            | 9                | P                     | 7.2                    |
| Ble-Castillo 2005| Mexico | α-tocopherol 800 IU/Com strach |               | 6              | 13             | 51.3            | 55.3              | 0       | 0                         | <14          | <14              | P                     | 10.9                   |
| Ballarsingh 2005| India  | Tocotrienols 6 mg/kg Rice brain oil |             | 8              | 10             | 48.5            | 52.6              | 50      | 55.6                      | 3.3          | 4.3              | C1                    | 7.6                    |
| Boshtam 2005   | Iran    | Vitamin E 200 IU/d            | Placebo       | 27             | 50             | 52.8            | 54.5              | —       | —                        | P            | 9.9              | 10.8                  | 10.5                   |
| Ward 2007      | Australia | RRR-α-tocopherol or mixed tocopherols 500 mg/d | Soy bean oil | 6              | 37             | 61              | 62                | 67.5    | 88.9                      | P            | 7.2              | 7.3                   | —                      |
| de Oliveira 2011| Brazil | α-tocopherol 800 IU/Placebo  |               | 16             | 25             | 62              | 63                | 72      | 57.7                      | P            | —                | —                     | 7.2                    |

FPG: fasting plasma glucose; vitE: vitamin E; mixed tocopherols: 60% γ-,25% δ- and 15% α-tocopherol; HbA1c: glycated hemoglobin; USA: United States of America; UK: The United Kingdom; T:treatment group; C: control group; C1: crossover design; P: Parallel design.

doi:10.1371/journal.pone.0095008.t001
P = 0.62) and -3.06 pmol/l (95% CI: -12.82, 6.70 pmol/l; P = 0.54), respectively.

Secondary outcomes

Pooled analysis of the changes in secondary outcomes was performed by calculating or estimating the weighted averages. These changes are summarised in Table 3. Vitamin E resulted in no significant decrease in HOMA-IR (-0.32, 95% CI: -0.65 to 0.01, P = 0.06) or postprandial glucose (-0.20, 95% CI: -1.07 to 0.67, P = 0.65) compared with controls. Vitamin E supplementation also appeared to have no statistically significant effect on lipid metabolism, including triglyceride (TG), total cholesterol (TC), low-density lipoprotein-cholesterol (LDL-C), and high-density lipoprotein-cholesterol (HDL-C), compared with placebo. Furthermore, vitamin E supplementation failed to significantly alter either systolic blood pressure (SBP) or diastolic blood pressure (DBP) compared with the control group.

Study quality and publication bias

The quality of these fourteen randomised controlled trials was variable (Table 4). Only one study was classified as high quality (Jadad score of 4) [37], and thirteen studies were classified as low quality (Jadad score of 2 or 3) [25–36,38]. Randomisation was a prerequisite for inclusion in this meta-analysis, so all studies were randomised, but only two trials mentioned the method for sequence generation [32,37]. Thirteen studies were double-blind [25–31,33–38], and one study did not describe blinding [32]. Ten trials presented a clear explanation for withdrawals and dropouts in each group [25,26,28,29,31–35,37].

The funnel plots of the studies were symmetric for HbA1c, fasting glucose and fasting insulin on visual examination. Furthermore, the results of the Egger’s test did not support the existence of publication bias for HbA1c (P = 0.46), fasting glucose (P = 0.87), or fasting insulin (P = 0.27).
Discussion

This meta-analysis of fourteen RCTs with 714 subjects demonstrated that vitamin E supplementation was not associated with the reduction in HbA1C, fasting glucose and fasting insulin. However, significant heterogeneity was detected in all three pooled analyses. Therefore, further subgroup analysis was performed to identify the source of heterogeneity. The subgroup analyses indicated that vitamin E supplementation significantly decreased both HbA1c and fasting insulin in studies with low serum vitamin E concentrations and poorer glycaemic control. Furthermore, larger vitamin E doses and longer study durations also benefited HbA1c and fasting insulin concentrations. Although this meta-analysis failed to identify significant correlations between vitamin E supplements and improvements in glycaemic control, our results suggest that T2DM subjects with low serum vitamin E concentrations or poorer glycaemic control may experience a positive change in glycaemic control after vitamin E supplementation.

Recent mechanistic studies have examined the effects of vitamin E on glycaemic control and provide further evidence for the biological plausibility of these findings. There is now considerable evidence that oxidative stress plays an important role in the glycation of haemoglobin [39] and beta-cell dysfunction [6] in T2DM. Vitamin E, a common antioxidant, suppresses ROS generation in the pancreas and maintains the structural integrity of pancreatic islets in experimental diabetes [8]. Furthermore, there is evidence that vitamins E supplementation inhibits the glycation of haemoglobin, a biomarker for the diagnosis of diabetes in clinical settings, by interrupting glycosylation at an early step in the Maillard reaction [40] or by partially inhibiting the formation of AGEs [11]. Moreover, in addition to its beneficial effects on the preservation of pancreatic beta cell function, vitamin E partially reverses the beta-cell apoptosis caused by oxidative stress [8,12].

Observational prospective cohorts and case-control studies have been performed to determine the effect of vitamin E supplementation on glycaemic control, although the results are conflicting. Observational prospective cohorts have indicated that low serum vitamin E concentrations are associated with a lower risk of diabetes. A large, 23-year population-based study involving 4304 middle-aged individuals from Finland revealed that vitamin E intake, including α-tocopherol γ-tocopherol, δ-tocopherol, and β-tocotrienol were significantly associated with a reduced risk of T2DM [9]. In contrast, some RCTs have demonstrated no association between vitamin E supplementation and the risk of T2DM [41]. Case-control trials also demonstrated that vitamin E supplementation exerts beneficial effects on glycaemic control, including serum HbA1c [27], fasting glucose [29] and fasting insulin [30] in T2DM subjects. In contrast, several studies have reported no positive correlations between vitamin E intake and glycaemic control in subjects with T2DM [33].

In this meta-analysis, subgroup analysis was performed on the basis of our predefined variances to identify sources of heterogeneity. It is reasonable to speculate that the treatment effects of vitamin E are influenced by its baseline levels. Subgroup analyses revealed that vitamin E supplementation has a more pronounced effect on HbA1c and fasting insulin in studies with low baseline serum vitamin E concentrations, which is consistent with the findings of an earlier meta-analysis by N. Sukomsomboon et. al [42]. This increased effect may indicate that extra vitamin E is needed for subjects with vitamin E deficiencies to antagonise oxidative stress, inhibit glycation of haemoglobin, and/or protect beta cell function. In those patients with poor glycaemic control, subjects with larger doses of vitamin E and longer treatment periods may experience increased benefits of vitamin E supplementation on HbA1c or fasting insulin control. It is possible that shorter T2DM trials may have been insufficient to detect true HbA1c and insulin changes; in addition, smaller doses of vitamin E may not sufficiently elevate vitamin E levels.

The analysis of our secondary outcomes revealed a tendency but no significant improvement in HOMA-IR, postprandial glucose and blood pressure in the vitamin E group compared with controls. In addition, vitamin E supplementation had no significant effect on lipid metabolism, which was consistent with the findings of an earlier meta-analysis by Shekelle PG [43].

The strength of this study was that trials included in this meta-analysis were all RCTs, which allow reliable inferences about causality. In addition, this meta-analysis assessed the effects of vitamin E supplementation on plasma concentrations of fasting glucose and fasting insulin for the first time. Furthermore, subgroup analyses were performed to detect sources of heterogeneity for primary outcomes.

Although we believe that the current meta-analysis provided useful information, some potential limitations should be addressed. First, in this meta-analysis, small trials with limited subjects were collected, which limited the ability to extrapolate the outcomes of
Table 2. Subgroup analyses of HbA1c, fasting glucose and fasting insulin stratified by previously defined study characteristics.

| Variables | HbA1c(%) | Fasting glucose(mmol/l) | Fasting insulin(pmol/l) |
|-----------|----------|------------------------|------------------------|
|           | No. of trials | Mean difference (95%CI) | P for heterogeneity | No. of trials | Mean difference (95%CI) | P for heterogeneity | No. of trials | Mean difference (95%CI) | P for heterogeneity |
| Subgroup analysis | | | | | | |
| Vitamin E dose | | | | | | |
| ≤400 mg/d | 4 | −0.01(−0.52,0.51) | 0.04 | 3 | 0.01(−0.85,0.87) | 0.23 | 2 | −6.56(−19.50,6.38) | 0.35 |
| >400 mg/d | 8 | −0.35(−0.63,−0.07) | 0.01 | 9 | 0.15(−0.38,0.68) | <0.0001 | 4 | −4.13(−14.48,6.21) | <0.0001 |
| Duration | | | | | | |
| Shorter term (<12 wk) | 6 | −0.17(−0.35,0.01) | 0.62 | 7 | 0.31(−0.68,1.29) | <0.001 | 3 | 0.33(−5.49,4.82) | 0.33 |
| Longer term (≥12 wk) | 6 | −0.33(−0.79,0.13) | 0.0004 | 5 | −0.14(−0.78,0.50) | <0.001 | 3 | −9.0(−15.90, −2.10) | 0.32 |
| Baseline HbA1c (%) | | | | | | |
| <8 | 8 | −0.12(−0.49,0.25) | 0.0002 | 6 | −0.55(−0.81,−0.29) | 0.19 | 1 | 1.00(−2.16,4.16) | - |
| ≥8 | 4 | −0.49(−0.71,−0.28) | 0.5 | 4 | 0.95(−0.70,2.59) | <0.001 | 5 | −10.67(−12.31, −9.02) | 0.64 |
| Baseline fasting glucose (mmol/l) | | | | | | |
| <8 | 2 | −1.18(−3.60,1.25) | 0.009 | 4 | −0.22(−0.78,0.35) | 0.87 | 2 | 0.44(−22.95,23.82) | 0.64 |
| ≥8 | 8 | −0.44(−0.62,−0.26) | 0.27 | 8 | 0.21(−0.34,0.77) | <0.0001 | 4 | −5.15(−14.48,4.18) | <0.0001 |
| Ethnicity | | | | | | |
| Asian | 5 | −0.21(−0.84,0.43) | 0.004 | 4 | −0.10(−0.67,0.46) | 0.39 | 2 | −6.56(−19.50,6.38) | 0.35 |
| Western | 7 | −0.34(−0.58,−0.09) | 0.05 | 8 | 0.15(−0.4,0.7) | <0.0001 | 4 | −4.13(−14.48,6.21) | <0.0001 |
| Baseline serum Vitamin E(mmol/l) | | | | | | |
| Normal | 6 | −0.23(−0.56,0.09) | 0.08 | 5 | −0.37(−0.87,−0.28) | 0.16 | 2 | −2.23(−12.42,7.96) | 0.15 |
| Low | 2 | −0.58(−0.83,−0.34) | 0.77 | 3 | 0.01(−0.13,0.15) | 0.39 | 3 | −9.0(−15.90, −2.10) | 0.32 |

doi:10.1371/journal.pone.0095008.t002
this review toward realistic public health recommendations for vitamin E supplementation for glycaemic control in T2DM. Second, there was considerable evidence of trial heterogeneity. Subgroup analyses revealed that vitamin E dosage, trial duration, glycaemic control, ethnic group and serum vitamin E levels may contribute to the variation in trial effects. Therefore, future studies focusing on the effects of different subject characteristics on changes in glycaemic control after vitamin E supplementation are needed to confirm our results. Third, the quality of RCTs included in this meta-analysis was varied. Of the fourteen trials, only one trial was a high-quality study; the other studies were of low quality, which may affect the confidence of this meta-analysis. Publication bias is also a potential limitation. We explored the possibility of publication bias using a funnel plot and Egger’s test and found that publication bias was unlikely to have significantly affected our study results. Fourth, our meta-analysis did not recognise a safety margin of vitamin E supplementation because no serious side effects were reported in the included trials. However, concern has been raised as to the safety of high-dose vitamin E supplementation. A meta-analysis by Miller ER demonstrated that vitamin E doses >400 IU per day in patients with chronic diseases may increase all-cause mortality by increasing the risk of prolonged bleeding time and antagonising vitamin K functions in individuals routinely ingesting various drugs [44].

In conclusion, to date, evidence from randomised, controlled trials suggests that vitamin E supplementation is insufficient to decrease serum HbA1c, fasting glucose and fasting insulin concentrations in subjects with T2DM. Subgroup analyses support the hypothesis that vitamin E supplementation significantly reduces HbA1c and fasting insulin concentrations in subjects with low serum vitamin E concentrations and poor glycaemic control. Future large-scale, randomised trials are needed to investigate the effect of vitamin E supplementation on glycaemic control and the potential benefits and toxicities in T2DM subjects.

Table 3. Summary of effect sizes (weighted mean difference) for secondary outcomes.

| Variables             | No. of comparison | Sample size | Net change (95% CI) | P      | Test for heterogeneity |
|-----------------------|-------------------|-------------|---------------------|--------|------------------------|
| TC (%)                |                   | T          | C                   |        |                        |
| HOMA index            | 3                 | 70         | 71                  | -0.32  | (-0.65, 0.01)          | 0.06  | 88                     | 0.0001 |
| Postprandial glucose  | 3                 | 69         | 69                  | -0.20  | (-1.07, 0.67)          | 0.65  | 0                      | 0.77   |
| Triglyceride (mmol/l) | 8                 | 201        | 212                 | -0.02  | (-0.29, 0.25)          | 0.90  | 96                     | <0.0001 |
| Total-C (mmol/l)      | 9                 | 254        | 252                 | -0.29  | (-0.85, 0.27)          | 0.31  | 99                     | <0.0001 |
| HDL-c (mmol/l)        | 9                 | 217        | 223                 | -0.00  | (-0.03, 0.02)          | 0.70  | 20                     | 0.27   |
| LDL-c (mmol/l)        | 8                 | 192        | 203                 | -0.24  | (-0.78, 0.29)          | 0.37  | 98                     | <0.0001 |

HOMA, homeostasis model assessment; Total-C, total cholesterol; HDL-C, high-density lipoprotein-cholesterol; LDL-C, low-density lipoprotein-cholesterol; CI, confidence interval. T: treatment group; C: control group.

doi:10.1371/journal.pone.0095008.t003

Table 4. Quality assessment of included studies.

| Authors          | Randomisation | Allocation concealment | Random sequence generation | Blinding | Reporng of withdrawals | Jadad score |
|------------------|---------------|------------------------|---------------------------|----------|------------------------|-------------|
| Paolisso 1993    | Y             | U                      | U                         | Y        | Y                      | 3           |
| Reaven 1995      | Y             | U                      | U                         | Y        | Y                      | 3           |
| Tutuncu 1998     | Y             | U                      | U                         | Y        | U                      | 2           |
| Gazis 1999       | Y             | U                      | U                         | Y        | Y                      | 3           |
| Paolisso 2000    | Y             | U                      | U                         | Y        | Y                      | 3           |
| Manzella 2001    | Y             | U                      | U                         | Y        | U                      | 2           |
| Park 2002        | Y             | U                      | U                         | Y        | Y                      | 3           |
| Chen 2004        | Y             | U                      | Y                         | U        | Y                      | 3           |
| Economides 2005  | Y             | U                      | U                         | Y        | Y                      | 3           |
| Ble-Castillo 2005| Y             | U                      | U                         | Y        | Y                      | 3           |
| Ballarsingh 2005 | Y             | U                      | U                         | Y        | Y                      | 3           |
| Boshtam 2005     | Y             | U                      | U                         | Y        | U                      | 2           |
| Ward 2007        | Y             | U                      | Y                         | Y        | Y                      | 4           |
| Oliveira 2011    | Y             | U                      | U                         | Y        | U                      | 2           |

Y, yes; U, unclear; Randomisation: the study described as randomized; Random sequence generation: the correct method for generation of random numbers computer random numbers table, shuffled cards or tossed coins, and minimization; Allocation concealment: Adequate concealment was that up to the point of treatment (eg, central randomisation); Double-blinding: masking to both researchers and patients; Reporting of withdrawals: The numbers and reasons for withdrawal in each group had to be stated for a point to be awarded.

doi:10.1371/journal.pone.0095008.t004
Supporting Information

Checklist S1  PRISMA Checklist.

Diagram S1  PRISMA 2009 Flow Diagram.

References

1. Whiting DR, Guariguata L, Weil C, Shaw J (2011) IDF diabetes atlas: global estimates of the prevalence of diabetes for 2011 and 2030. Diabetes Res Clin Pract 94: 311–321.

2. Arredondo A (2011) Diabetes: a global challenge with high economic burden for public health systems and society. Am J Public Health 101: e1–2.

3. Paolisso G, Esposito R, D’Alesso MA, Barbieri M (1999) Primary and secondary prevention of atherosclerosis: is there a role for antioxidants? Diabetes Metab 25: 405–406.

4. Madiyan AG, Myacle AD, Diaz-Maldonado N, Rochelle NS, Janle EM, et al. (2011) Differential carbonylation of proteins as a function of in vivo oxidative stress. J Proteome Res 10: 3959–3972.

5. Krouskop TA, Tawfik H, Khoaldadi I, Amri I (2011) Relationship between advanced glycation end products and increased lipid peroxidation in semen of diabetic men. Diabetes Res Clin Pract 91: 61–66.

6. Robertson RP (2004) Chronic oxidative stress as a central mechanism for glucose toxicity in pancreatic islet beta cells in diabetes. J Biol Chem 279: 42351–42354.

7. Robertson RP, Harmon JS (2006) Diabetes, glucose toxicity, and oxidative stress: A case of double jeopardy for the pancreatic islet beta cell. Free Radical Biol Med 41: 178–188.

8. Pazdro R, Burgess JR (2010) The role of vitamin E and oxidative stress in diabetes complications. Mech Ageing Dev 131: 276–286.

9. Mononen J, Knekt P, Jarvinen R, Reunanen A (2004) Dietary antioxidant intake and risk of type 2 diabetes. Diabetes Care 27: 362–366.

10. Farvid MS, Jalali M, Sassi F, Hosseini M (2005) Comparison of the effects of vitamins and/or mineral supplementation on glucomerul and tubular dysfunction in type 2 diabetes. Diabetes Care 28: 2458–2464.

11. Minunzayama Y, Takomura S, Bito Y, Shinkawa H, Takeda T, et al. (2000) Supplementation of alpha-tocopherol improves cardiovascular risk factors via the insulin signalling pathway and reduction of mitochondrial reactive oxygen species in type II diabetic rats. Free Radical Res 42: 261–271.

12. Jin L, Xu HY, Jin LJ, Li SY, Xu YP (2006) Antioxidant and pancreas-protective effect of auibin on rats with streptozotocin-induced diabetes. Eur J Pharmacol 502: 162–167.

13. Sanyal AJ, Chalasani N, Kowdley KV, McCullough A, Diehl AM, et al. (2010) Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med 362: 1673–1685.

14. Cui YH, Jing CX, Pan HW (2013) Association of blood antioxidants and vitamins with risk of age-related cataract: a meta-analysis of observational studies. Am J Clin Nutr 90: 776–786.

15. Myung SK, Ju W, Cho B, Oh SW, Park SM, et al. (2013) Efficacy of vitamin and antioxidant supplements in prevention of cardiovascular disease: systematic review and meta-analysis of randomised controlled trials. BMJ 346: f10.

16. Bin Q, Hu X, Cao Y, Gao F (2011) The role of vitamin E (tocopherol) supplementation in the prevention of stroke. A meta-analysis of 13 randomised controlled trials. Thromb Haemost 105: 579–585.

17. Ratliff K, Bindewald B, Hughes J, Erwin B, Swanson C, et al. (2004) Dietary supplement use by US adults: data from the National Health and Nutrition Examination Survey, 1999-2000. Am J Epidemiol 160: 339–349.

18. Moher D, Pham B, Jones A, Cook DJ, Jadad AR, et al. (1998) Does quality of reports of randomised trials affect estimates of interventional efficacy reported in meta-analyses? Lancet 352: 699–613.

19. Anzueto-Cabeza J, Sarpaturwi A, Higgins JP (2011) Expressing findings from meta-analyses of continuous outcomes in terms of risks. Stat Med 30: 2967–2985.

20. Follmann D, Elliott P, Suh I, Cutler J (1992) Variance imputation for overviews of clinical trials with continuous response. J Clin Epidemiol 45: 769–773.

21. Higgins JP, Thompson SG (2002) Quantifying heterogeneity in a meta-analysis. Stat Med 21: 1539–1558.

22. DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Control Clin Trials 7: 177–188.

23. Egger M, Davey Smith G, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315: 629–634.

24. Paulus G, D’Amore A, Galvezano D, Balvi Y, Giugliano D, et al. (1993) Daily vitamin E supplements improve metabolic control but not insulin secretion in elderly type II diabetic patients. Diabetes Care 16: 1433–1437.

25. Reaven PD, Herold DA, Barnett J, Edelman S (1995) Effects of Vitamin E on susceptibility of low-density lipoprotein and low-density lipoprotein substitutions to oxidation and on protein glycation in NIDDM. Diabetes Care 18: 807–816.

26. Tutuncu NB, Bayraktar M, Varli K (1998) Reversal of defective nerve conduction with vitamin E supplementation in type 2 diabetes: a preliminary study. Diabetes Care 21: 1915–1918.

27. Gasz A, White DJ, Page SR, Cockcroft JR (1999) Effect of oral vitamin E (alpha-tocopherol) supplementation on vascular endothelial function in Type 2 diabetes mellitus. Diabet Med 16: 304–311.

28. Paulus G, Tagliamonte MR, Barbieri M, Zito GA, Gambardella A, et al. (2000) Chronic vitamin E administration improves brachial reactivity and increases intracellular magnesium concentration in type II diabetic patients. J Clin Endocrinol Metab 85: 109–115.

29. Manouel D, Barbieri M, Ragni E, Paolisso G (2001) Chronic administration of pharmacologic doses of vitamin E improves the cardiac autonomic nervous system in patients with type 2 diabetes. Am J Clin Nutr 73: 1052–1057.

30. Park S, Choi SB (2002) Effects of alpha-tocopherol supplementation and continuous subcutaneous insulin infusion on oxidative stress in Korean patients with type 2 diabetes. Am J Clin Nutr 75: 728–733.

31. Son JW, Jang EH, Kim MK, Kim IT, Roh YJ, et al. (2011) Diabetic retinopathy is associated with subclinical atherosclerosis in newly diagnosed type 2 diabetes mellitus. Diabetes Res Clin Pract 91: 253–259.

32. Economides PA, Khaohliar L, Casselli A, Caballero AE, Keenan H, et al. (2005) The effect of vitamin E on endothelial function of micro- and macrocirculation and left ventricular function in type 1 and type 2 diabetic patients. Diabetes 54: 294–211.

33. Ble-Castillo JL, Carmona-Diaz E, Mendez JD, Larrios-Medina FJ, Medina-Santillan R, et al. (2005) Effect of alpha-tocopherol on the metabolic control and oxidative stress in female type 2 diabetics. Biomed Pharmacother 59: 290–295.

34. Balasubringi S, Beg ZH, Ahamed J (2005) The therapeutic impacts of tocotrienols in type 2 diabetic patients with hyperlipidemia. Atherosclerosis 182: 367–374.

35. Boshkat M, Rafei M, Gholshadi ID, Ani M, Shirani Z, et al. (2005) Long term effects of oral vitamin E supplement in type II diabetic patients. Int J Vitam Nutr Res 75: 341–346.

36. Ward NC, Wu JH, Clarke MW, Padby JB, Burke V, et al. (2007) The effect of vitamin E on blood pressure in individuals with type 2 diabetes: a randomized, double-blind, placebo-controlled trial. J Hypertens 25: 227–234.

37. de Oliveira AM, Rondo PH, Luzia LA, D’Abronzo FH, Illison VK (2011) The effect of lipic acid and alpha-tocopherol supplementation on the lipid profile and insulin sensitivity of patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled trial. Diabetes Res Clin Pract 92: 253–260.

38. Monnier L, Mas E, Ginet C, Michel F, Villon L, et al. (2006) Activation of the insulin signalling pathway and reduction of mitochondrial reactive oxygen stress: A case of double jeopardy for the pancreatic islet beta cell. Free Radic Biol Med 41: 1763–1685.

39. Monnier L, Mas E, Ginet C, Michel F, Villon L, et al. (2006) Activation of the insulin signalling pathway and reduction of mitochondrial reactive oxygen stress: A case of double jeopardy for the pancreatic islet beta cell. Free Radic Biol Med 41: 1763–1685.

40. Shekelle PG, Morton SC, Jungvig LK, Udani J, Spar M, et al. (2004) Effect of pharmacologic reagents/materials/analysis tools: AT SZ. Wrote the paper: RX GC. Contributed to experiments: RX GC MZ. Analyzed the data: AT SZ. Contributed reagents/materials/analysis tools: AT SZ. Wrote the paper: RX GC.

Author Contributions

Conceived and designed the experiments: RX GC MZ. Performed the experiments: RX GC MZ. Analyzed the data: AT SZ. Contributed reagents/materials/analysis tools: AT SZ. Wrote the paper: RX GC.